METUCHEN, N.J.--(BUSINESS WIRE)--Tevogen Bio, a clinical stage biotechnology company, announced that its investigational COVID-19 therapy, TVGN-489, demonstrated strong antiviral activity against SARS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback